Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Clin Cancer Res. 2018 May 30;24(18):4416–4428. doi: 10.1158/1078-0432.CCR-17-3649

Figure 1. Best overall response, OS and PFS of 74 metastatic melanoma patients following TIL ACT.

Figure 1

(A) Clinical response is stratified by complete response (CR) and partial response (PR). (B) Overall survival (black line) and progression-free survival (pink line) post-TIL ACT of the same cohort.